25.01.2017 21:40:00
|
Johnson & Weaver, LLP Announces Investigations of Pearson plc., BT Group plc, Dr. Reddy's Laboratories Ltd. and OneMain Holdings, Inc.
SAN DIEGO, Jan. 25, 2017 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP, is investigating potential claims against Pearson plc, BT Group plc, Dr. Reddy's Laboratories Ltd., and OneMain Holdings, Inc., as detailed below:
Pearson plc
Shareholder rights law firm Johnson & Weaver, LLP continues its investigation of potential violations of the federal securities laws by Pearson plc (NYSE: PSO) and certain of its officers.
On January 18, 2017, Pearson said that its initial projections about its U.S. educational business had been too high and students are balking at paying top-dollar for textbooks when more affordable alternatives to outright purchases are available. The result has been an excess of unsold books. Pearson also signaled that a dividend cut would be coming in 2017. Pearson shares were down 29% on January 18, 2017.
After Pearson's announcement, Moody's Investors Service changed the outlook on the Company ratings to negative from stable.
If you have information that could assist in this investigation, or if you are a Pearson shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-814-4471. If emailing, please include a phone number where you can be reached.
BT Group plc
Shareholder Rights Law Firm Johnson & Weaver, LLP announces the filing of a class action lawsuit on behalf of purchasers of BT Group plc (NYSE: BT) from March 3, 2015, through November 7, 2016, both dates inclusive (the "Class Period"). The lawsuit seeks to recover damages for BT investors under the federal securities laws.
According to the lawsuit, throughout the Class Period Defendants made false and misleading statements and failed to disclose that: (1) BT Group misstated its earnings due to improper accounting practices and improper sales, purchase, factoring and leasing transactions in its Italian operations; (2) BT Group lacked effective internal controls; and (3) as a result, Defendants' statements about BT Group's business, operations and prospects were materially false and misleading and lacked a reasonable basis at all relevant times.
If you wish to serve as a lead plaintiff, you must move the Court no later than March 27, 2017. If you wish to discuss this action, have any questions concerning this notice, or your rights or interests, please contact Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-814-4471. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Dr. Reddy's Laboratories Ltd.
Shareholder rights law firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Dr. Reddy's Laboratories Ltd.(NYSE: RDY) and certain of its officers. Dr. Reddy's operates as an integrated pharmaceutical company worldwide.
On November 6, 2015, Dr. Reddy's reported that the Company received a "warning letter" from U.S. regulators over inadequate quality controls at three manufacturing plants producing drugs for cancer and other diseases.
Dr. Reddy's said the FDA warning meant it would not receive U.S. approvals for drugs made at the plants until it fixed the problems. The manufacturing plants account for more than 10 percent to 12 percent of Dr. Reddy's sales.
If you have information that could assist in this investigation, or if you are a Dr. Reddy's shareholder and purchased before November 9, 2015, and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-814-4471. If emailing, please include a phone number where you can be reached.
OneMain Holdings, Inc.
Shareholder Rights Law Firm Johnson & Weaver, LLP announces the filing of a class action lawsuit on behalf of purchasers of OneMain Holdings, Inc. securities (NYSE: OMF) from March 3, 2015, through November 7, 2016, both dates inclusive (the "Class Period"). The lawsuit seeks to recover damages for OneMain investors.
According to the lawsuit, defendants throughout the Class Period caused OneMain to issue materially misleading representations and omit material information regarding the projected net income to be achieved by OneMain following, and in large part due to, the combination of OneMain Financial with Springleaf and the purported synergies achieved by the combined company.
If you wish to serve as a lead plaintiff, you must move the Court no later than March 20, 2017. If you wish to discuss this action, have any questions concerning this notice, or your rights or interests, please contact lead analyst Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-814-4471. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.
Contact:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--weaver-llp-announces-investigations-of-pearson-plc-bt-group-plc-dr-reddys-laboratories-ltd-and-onemain-holdings-inc-300396847.html
SOURCE Johnson & Weaver, LLP
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu OneMain Holdings Incmehr Nachrichten
29.10.24 |
Ausblick: OneMain stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) | |
15.10.24 |
Erste Schätzungen: OneMain gewährt Anlegern Blick in die Bücher (finanzen.net) | |
30.07.24 |
Ausblick: OneMain präsentiert Quartalsergebnisse (finanzen.net) | |
16.07.24 |
Erste Schätzungen: OneMain stellt Zahlen zum jüngsten Quartal vor (finanzen.net) |
Analysen zu OneMain Holdings Incmehr Analysen
Aktien in diesem Artikel
Dr. Reddy's Laboratories Ltd. (Spons. ADRS) | 13,20 | -0,75% | |
OneMain Holdings Inc | 54,10 | -0,41% | |
Pearson PLCShs Sponsored American Deposit.Receipt Repr. 1 Sh | 15,49 | 0,13% |